Table 2.
Ages of ASCA, GAB, PAB, and ANCA in patients with IBD.
| Antibodies | Median (IQR), years | P value | |
|---|---|---|---|
| Positive | Negative | ||
| ASCA IgG | 40.0 (25.0-63.0) | 39.0 (26.0-54.0) | 0.0615 |
| ASCA IgA | 43.0 (23.8-64.3) | 39.0 (26.0-53.0) | 0.0203 |
| GAB IgG | 37.0 (26.8-53.0) | 41.0 (25.0-56.0) | 0.3446 |
| GAB IgA | 31.5 (23.3-49.8) | 39.0 (26.0-55.0) | 0.0887 |
| PAB IgG | 27.5 (22.0-34.0) | 42.0 (27.0-56.0) | <0.0001 |
| PAB IgA | 26.0 (20.0-33.0) | 40.0 (26.0-55.3) | <0.0001 |
| ANCA IgG | 45.0 (31.0-57.0) | 39.0 (25.0-54.0) | 0.0019 |
| ANCA IgA | 44.5 (31.3-55.8) | 39.0 (25.0-55.0) | 0.0110 |
Data were presented as median (IQR) and calculated by Mann–Whitney test. IQR: interquartile range; ASCA: anti-Saccharomyces cerevisiae antibodies; GAB: anti-intestinal goblet cell antibodies; PAB: antibodies to exocrine pancreas; ANCA: anti-neutrophil cytoplasmic antibodies; IBD: inflammatory bowel disease. P values indicate differences between antibody positive and negative patients. P < 0.05 was considered statistically significant.